Quest Diagnostics: 3 Key Takeaways for Long-Term Investors

On its third quarter of 2026 earnings call, held on Oct. 22, 2026, Quest Diagnostics (NYSE:DGX) reported 10% revenue growth and raised its guidance for full-year revenue and diluted earnings per share (EPS), which measures net income per common share. For long-term investors, the company's expanding digital channels and laboratory automation provide clear operational leverage. Three things management said stand out.

1. Apple Health Partnership Drives Rapid Growth in Consumer Diagnostics

Quest Diagnostics expects full-year consumer health revenue growth to exceed 30%, bolstered by higher-margin direct-to-consumer order flow that eliminates insurance billing friction.

Users of the Apple Health app will be able to seamlessly purchase, schedule, and receive test results for over 50 biomarkers, including ApoB and Lp(a), all within the app.
-- Jim Davis, Chairman, Chief Executive Officer, and President

2. Laboratory Automation and Artificial Intelligence Boost Operating Margins

The company offsets wage inflation through its Invigorate cost-reduction program by automating specimen aliquoting, which is the process of splitting test samples into smaller portions, across its core diagnostic facilities.

Automation and AI continue to be major drivers of improvements in quality, productivity, and efficiencies.
-- Jim Davis, Chairman, Chief Executive Officer, and President

3. Management Fights Flawed Medicare Reimbursement Cuts With Federal Advocacy

Proposed rate reductions under PAMA, or the Protecting Access to Medicare Act, threaten a 1% top-line hit in 2027, prompting Quest Diagnostics to lobby for reform legislation.

We continue to advocate for the passage of the bipartisan, bicameral RESULTS Act to permanently reform PAMA to ensure the data used to set rates properly reflects the market. Over 135 co-sponsors in Congress share our concerns about PAMA and our commitment to RESULTS.
-- Jim Davis, Chairman, Chief Executive Officer, and President

Looking Ahead

Patient testing demand is expanding across core channels, pushing leadership to raise full-year revenue targets. Strategic hospital collaborations and expanded nephrology coverage reinforce market scale while management tracks pricing discipline and federal fee schedules.

Our robust organic revenue growth demonstrates that our solutions are fulfilling the expanding clinical care needs of an aging population, as well as the increasing number of people focused on prevention and wellness.
-- Jim Davis, Chairman, Chief Executive Officer, and President

Operational efficiency programs and direct-to-consumer expansion protect operating margins against prospective legislative headwinds and staffing increases.

There are always going to be more efficiencies in the lab. But given the incredibly strong volume growth that we have right now, we have to keep the frontline physician staffed in order to handle the volume. The best way to offset this is to grow our way out of it.
-- Jim Davis, Chairman, Chief Executive Officer, and President

The Motley Fool has positions in and recommends Quest Diagnostics. The Motley Fool has a disclosure policy.